Clinical Research Directory
Browse clinical research sites, groups, and studies.
Effects of Sitagliptin in Individuals With Genetically Decreased DPP4
Sponsor: University of Pennsylvania
Summary
This is a pilot clinical trial to test the hypothesis that during sitagliptin (DPP4 inhibitor), individuals heterozygous for DPP4 loss of function variants will have a reduction in DPP4 activity and antigen, lower glucose after a mixed meal, and higher levels of intact DPP4 substrates compared to during placebo and compared to matched controls.
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2020-08-26
Completion Date
2026-02-28
Last Updated
2026-01-16
Healthy Volunteers
No
Interventions
Sitagliptin 100mg
Sitagliptin will be administered daily for 7 days, with a study day on day 7.
Placebo Oral Tablet
Placebo will be administered daily for 7 days, with a study day on day 7.
Locations (1)
University of Pennsylvania
Philadelphia, Pennsylvania, United States